摘要
目的探讨恩替卡韦抗病毒治疗对肝癌HBV感染患者术后预后的影响。方法将80例行根治性切除术的肝癌患者按HBV-DNA水平区分为高病毒复制组(HBV-DNA载量≥105copies/m L)与低病毒复制组(HBV-DNA载量<105copies/m L),分别比较两组行恩替卡韦抗病毒治疗与未行抗病毒治疗患者间的术后肝功能、HBV-DNA水平和并发症发生率。结果无论是高病毒复制组还是低病毒复制组,行抗病毒治疗患者肝功能恢复均优于未行抗病毒治疗患者,且HBV-DNA水平较未行抗病毒治疗的患者明显降低,差异均有统计学意义(P<0.05);两组中行抗病毒治疗患者的术后并发症发生率均低于未行抗病毒治疗的患者,其中术后并发症发生率差异在低病毒复制组中有统计学意义(8.70%vs 39.13%,P=0.038)。结论抗病毒治疗能明显改善肝癌合并HBV感染患者术后的肝功能和病毒学指标,具有一定的应用价值。
[ Objective ] To assess the effects of antiviral therapy with Entecavir on postoperative prognosis for liv- er cancer patients infected with hepatitis B virus. [ Methods ] Eighty patients undergoing radical resection for liver cancer were divided into high-level viral replication group （load level of HBV-DNA≥ 10^ 5copies/mE） and low-level viral replication group （load level of HBV-DNA〈10^5 copies/mL）, according to their HBV-DNA levels. The postopera- tive hver function, HBV-DNA levels and incidence of complications between patients receiving antiviral therapy with Entecavir and those who did not were compared within each group. [ Results ] In either high-level viral repli- cation group or low-level viral rephcation group, patients with antiviral treatment had better recovery of liver func- tion and lower HBV-DNA levels than those without antiviral treatment, and all differences reached a statistical sig- nificance （all P 〈0.05）; in either group, the incidence of postoperative complications was decreased in patients who received antiviral treatment compared with those without antiviral treatment, and difference in incidence of postoper- ative complications in low-level viral replication group reached statistical significance（8.70% vs. 39.13%, P =0.038）. [ Conclusions ] Antiviral therapy can effectively improve the postoperative liver function and virological indexes of liver cancer patients, so it has certain value in clinical practice.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第33期90-93,共4页
China Journal of Modern Medicine
关键词
癌
肝细胞
乙型肝炎
肝切除术
抗病毒药
carcinoma
hepatocellular
hepatitis B
hepatectomy
antivira! agents
